Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 48.7% in May

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 57,617 shares, a decrease of 48.7% from the April 30th total of 112,316 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 186,884 shares, the days-to-cover ratio is currently 0.3 days.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD traded down $0.02 during midday trading on Monday, hitting $0.74. The company’s stock had a trading volume of 188,870 shares, compared to its average volume of 1,870,922. The stock has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.57 and a beta of 0.73. The stock’s 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.74. Galmed Pharmaceuticals has a fifty-two week low of $0.41 and a fifty-two week high of $2.34.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Galmed Pharmaceuticals has a consensus rating of “Sell”.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.